1. Home
  2. Vaccines, Blood & Biologics
  3. Development & Approval Process (CBER)
  4. 2026 Biological License Application Approvals
  1. Development & Approval Process (CBER)

2026 Biological License Application Approvals

This list reflects information regarding the applications as of the approval date. It is not updated with regard to applicant or application status changes. The applications are listed by date of approval.

2026 Biological License Application Approvals
Tradename/Proper Name     Indication for UseSTNManufacturer/
License Number
Approval Date

OTARMENI

lunsotogene parvec-cwha

 

Indicated for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear.125874/0

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Rd
Tarrytown, NY 10591

Lic. # 1760
 

04/23/2026

KRESLADI

marnetegragene autotemcel

Indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant.
 
125806/0    

Rocket Pharmaceuticals, Inc.

9 Cedarbrook Drive
Cranbury, NJ 08512

Lic. # 2328

03/26/2026
Procleix Plasmodium Assay

Procleix Plasmodium Assay
Intended for use in screening individual human donors, including donors of whole blood and blood components, and in screening living donors of organ and tissue samples when specimens are obtained while the donor’s heart is still beating. It is not intended for use on cord blood specimens. Whole blood donor samples are tested individually.125862/0Grifols Diagnostic Solutions, Inc.

10804 Willow Court San Diego, CA 92127

Lic. # 2032
03/16/2026
Back to Top